New York State Teachers Retirement System Reduces Holdings in Axon Enterprise, Inc. (NASDAQ:AXON)

New York State Teachers Retirement System lessened its stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 5.6% during the third quarter, Holdings Channel.com reports. The institutional investor owned 66,247 shares of the biotechnology company’s stock after selling 3,939 shares during the period. New York State Teachers Retirement System’s holdings in Axon Enterprise were worth $26,472,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the stock. Blue Trust Inc. lifted its position in shares of Axon Enterprise by 987.5% in the second quarter. Blue Trust Inc. now owns 87 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 79 shares in the last quarter. Quent Capital LLC boosted its stake in shares of Axon Enterprise by 1,875.0% during the 3rd quarter. Quent Capital LLC now owns 79 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 75 shares during the last quarter. Asset Dedication LLC purchased a new stake in shares of Axon Enterprise during the second quarter worth about $47,000. Friedenthal Financial acquired a new position in shares of Axon Enterprise in the third quarter valued at approximately $51,000. Finally, Cullen Frost Bankers Inc. purchased a new position in shares of Axon Enterprise during the second quarter valued at approximately $59,000. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Axon Enterprise Stock Performance

Shares of AXON stock opened at $423.50 on Friday. The company has a current ratio of 2.88, a quick ratio of 2.52 and a debt-to-equity ratio of 0.35. The company has a market cap of $31.96 billion, a PE ratio of 123.83, a P/E/G ratio of 11.91 and a beta of 0.94. The company’s fifty day simple moving average is $400.22 and its 200-day simple moving average is $339.14. Axon Enterprise, Inc. has a 52 week low of $199.50 and a 52 week high of $455.17.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, beating the consensus estimate of $1.02 by $0.18. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. The company had revenue of $504.00 million for the quarter, compared to analyst estimates of $478.35 million. During the same period last year, the company posted $0.80 earnings per share. The firm’s revenue was up 34.5% compared to the same quarter last year. As a group, equities research analysts anticipate that Axon Enterprise, Inc. will post 1.79 EPS for the current year.

Insider Buying and Selling

In other Axon Enterprise news, Director Michael Garnreiter sold 1,000 shares of the stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $437.98, for a total value of $437,980.00. Following the completion of the sale, the director now owns 26,259 shares of the company’s stock, valued at $11,500,916.82. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Michael Garnreiter sold 1,000 shares of the firm’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $437.98, for a total transaction of $437,980.00. Following the completion of the sale, the director now directly owns 26,259 shares of the company’s stock, valued at approximately $11,500,916.82. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Julie A. Cullivan sold 900 shares of the business’s stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $353.53, for a total transaction of $318,177.00. Following the completion of the transaction, the director now owns 3,653 shares in the company, valued at $1,291,445.09. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 371,172 shares of company stock valued at $137,000,162. Corporate insiders own 6.10% of the company’s stock.

Analyst Ratings Changes

AXON has been the subject of several recent analyst reports. Barclays lifted their target price on shares of Axon Enterprise from $381.00 to $387.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. The Goldman Sachs Group lifted their price objective on Axon Enterprise from $385.00 to $441.00 and gave the company a “buy” rating in a research report on Wednesday, October 23rd. Northland Securities increased their target price on Axon Enterprise from $330.00 to $365.00 and gave the stock an “outperform” rating in a research report on Thursday, August 8th. Needham & Company LLC raised their price target on Axon Enterprise from $400.00 to $525.00 and gave the stock a “buy” rating in a research note on Tuesday, October 22nd. Finally, Craig Hallum upped their price objective on shares of Axon Enterprise from $370.00 to $376.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $388.23.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.